FIRST TIME VISITOR? CLICK HERE!

Welcome to AIDS-Drugs-Online.com.

Our website ensures an easy ordering process for affordable HIV/AIDS and PrEP medications, as well as protection of our customers' information. Having an account on our website allows you to place your orders easily, upload your prescriptions safely, view your order history, and even earn discounts.

If you have not ordered from us before:
You can create an account for free by clicking here.

Please take a moment to learn how to order. If you have any trouble, please call us at 1-888-243-7675.

Australia: +61 (2) 90537441 Switzerland: +41 (44) 7982088

We invite you to explore our website and save money on your HIV/AIDS and PrEP medications!


Odefsey 200/25/25mg
30 tablet(s)

Odefsey 200/25/25mg

$1,471.99 USD
+ shipping and handling
0 Review(s)

Prescription required

Active Ingredient(s): Emtricitabine/Rilpivirine/Tenofovir
Manufacturer: Gilead Science Inc.
Brand: Yes
Country of origin: Canada
30 tablet(s)
Active Ingredient(s): Emtricitabine/Rilpivirine/Tenofovir
Manufacturer: Gilead Science Inc.
Brand: Yes
Country of origin: Canada
Knows Names:

ODEFSEY is an oral combination formulation of the HIV Nucleoside analog Reverse Transcriptase Inhibitor (NRTI) drugs emtricitabine (200mg) and tenofovir alafenamide fumarate (25mg), and the second-generation Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) rilpivirine (25mg). ODEFSEY is used as a complete regimen for treatment of HIV-1 infection in certain patients, and should not be administered with other antiretroviral medications.

Dosing & Administration

ODEFSEY is indicated for the treatment of HIV infection in adults and children weighing 35 kg or more who meet specific criteria related to their treatment history, HIV RNA concentration, and evidence of virologic failure. Specifics are given in the product monograph. ODEFSEY is dosed as one tablet per day, taken with food. ODEFSEY comes in a film-coated tablet.

COMPLERA can be used without dosage adjustment in patients with a creatinine clearance >=30 mL/min, but is not recommended for use in patients with renal function below that level. Dosage adjustments are not needed for mild or moderate hepatic impairment, but safety and efficacy have not been established for use in severe hepatic impairment.

Contraindications

ODEFSEY is contraindicated in patients with hypersensitivity to any of its components, and in patients who are taking certain other medications listed in the product monograph.

Side Effects

ODEFSEY is associated with viral resistance, immune reconstitution syndrome, osteonecrosis, headache, insomnia, diarrhea, dizziness, nausea, fatigue, rash, and abnormal dreams. A more complete list of potential adverse effects is provided in the product monograph.

Precautions

ODEFSEY is not indicated for the treatment of hepatitis infections. Patients who are co-infected with HIV and Hepatitis B virus (HBV) or Hepatitis C virus (HCV) may be at higher risk of treatment-related hepatotoxicity. Severe acute exacerbations of HBV disease may occur when discontinuing ODEFSEY. All patients who test positive for HIV infection should be screened for comorbid HBV and HCV infection. Co-infected patients should be started on an antiretroviral regimen targeting co-infected viruses, regardless of CD4 counts or viral loads. Current HIV treatment guidelines outline drug regimens and prescribing considerations.

ODEFSEY has been associated with severe skin and hypersensitivity reactions, as well as hepatotoxicity, lactic acidosis and hepatomegaly with steatosis, new or worsening renal impairment, Fanconi syndrome, bone mineral density (BMD) loss, depressive disorders, suicidal ideation/behavior, and QTc prolongation. All of these can be serious or life threatening. Screening and monitoring guidelines are detailed in the product monograph.

Drug Interactions

ODEFSEY is associated with a large number of drug-drug and herbal interactions, cautions, and contraindications. These are listed in the product monograph.

Pregnancy & Lactation

Highly active retroviral combination treatment should be used in all pregnant women. There is insufficient data to characterize the safety of ODEFSEY use in pregnancy. Current guidelines should be consulted when treating pregnant women. Components of ODEFSEY are excreted in breast milk. The CDC recommends that all HIV positive women, treated or untreated, avoid breastfeeding to prevent vertical transmission of the virus.

Overdosage

ODEFSEY overdose should be treated with standard supportive care and monitoring. Some components of ODEFSEY are partially dialyzable.

There are no reviews yet
Be the first to review “Odefsey 200/25/25mg”
Star

Reviews are only written by verified customers who have purchased this product.

Related Products

Tenvir EM

Tenvir EM

from $65.00 USD
Abamune-L 600/300 Mg

Abamune-L 600/300 Mg

from $98.00 USD
Viraday

Viraday

from $98.00 USD
Efavir 600mg

Efavir 600mg

from $65.00 USD

Reset your password

Please enter your email below, and we will send you a new password.

Still having trouble signing in?

If you're unable to reset your password, please call Customer Service at 1-888-243-7675.